{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:11:36Z","timestamp":1772770296365,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.02.028","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T10:07:52Z","timestamp":1470737272000},"page":"S82-S85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S","title":["Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome\u2013Positive Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"16","author":[{"given":"Jorge Luis","family":"\u00c1ngeles-Vel\u00e1zquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Hurtado-Monroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Vargas-Viveros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Carrillo-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrna","family":"Candelaria-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.02.028_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.suponc.2011.08.001","article-title":"Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner","volume":"12","author":"Cornelison","year":"2012","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.clml.2016.02.028_bib2","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","article-title":"ESMO Guidelines Working Group, Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Baccarani","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.02.028_bib3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph\u2032 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.clml.2016.02.028_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1634\/theoncologist.6-3-233","article-title":"STI571: targeting BCR-ABL as therapy for CML","volume":"6","author":"Mauro","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2016.02.028_bib5","series-title":"Cancer Statistics Review (CSR), 1975-2011","author":"Surveillance, Epidemiology, and End Results (SEER)","year":"2014"},{"key":"10.1016\/j.clml.2016.02.028_bib6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3816\/CLK.2008.n.016","article-title":"Imatinib compared with imatinib\/cytarabine for the first-line treatment of early Philadelphia chromosome\u2013positive chronic myeloid leukemia: results of a randomized clinical trial of the Mexican Collaborative Leukemia Group","volume":"2","author":"Hurtado-Monroy","year":"2008","journal-title":"Clin Leuk"},{"key":"10.1016\/j.clml.2016.02.028_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0749-2081(03)00007-X","article-title":"Diagnosis, treatment, and nursing care of patients with chronic leukemia","volume":"19","author":"Breed","year":"2003","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.clml.2016.02.028_bib8","first-page":"324","article-title":"The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival","volume":"84","author":"Cervantes","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.028_bib9","first-page":"114","article-title":"Chronic myelogenous leukemia treatment and monitoring","volume":"107","author":"Von Bubnoff","year":"2010","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clml.2016.02.028_bib10","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.028_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/asheducation-2002.1.111","article-title":"Chronic myelogenous leukemia","volume":"1","author":"Druker","year":"2002","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2016.02.028_bib12","first-page":"1","article-title":"Therapy of chronic myeloid leukemia: twilight of the imatinib era?","author":"Trela","year":"2014","journal-title":"Oncology 2014"},{"key":"10.1016\/j.clml.2016.02.028_bib13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.02.028_bib14","series-title":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 4","year":"2014"},{"key":"10.1016\/j.clml.2016.02.028_bib15","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03","year":"2010"},{"key":"10.1016\/j.clml.2016.02.028_bib16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.028_bib17","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.028_bib18","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.028_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/B:QURE.0000015297.91158.01","article-title":"The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers","volume":"13","author":"Bacik","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2016.02.028_bib20","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study","volume":"21","author":"Hahn","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.028_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/j.clml.2016.02.028_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.clml.2016.02.028_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.028_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1185\/03007990903479299","article-title":"Management of chronic myeloid leukemia in clinical practice in France: results of the French subset of patients from the UNIC study","volume":"26","author":"Michallet","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2016.02.028_bib25","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow- up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.028_bib26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"Le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.028_bib27","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.028_bib28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cam4.440","article-title":"Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL\/ABL ratio at 3 months","volume":"4","author":"Casado","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2016.02.028_bib29","first-page":"1000","article-title":"Long-term outcomes of nilotinib treatment for chronic myelogenous leukemia patients with imatinib resistance or intolerance","volume":"7","author":"Wei","year":"2012","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.clml.2016.02.028_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"1","author":"Bixby","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2016.02.028_bib31","doi-asserted-by":"crossref","first-page":"RRN1204","DOI":"10.1371\/currents.RRN1204","article-title":"BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. National Library of Medicine; National Institutes of Health. Version 2","volume":"2","author":"Terasawa","year":"2011","journal-title":"PLoS Curr"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:52Z","timestamp":1761870592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016000835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":31,"alternative-id":["S2152265016000835"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.028","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome\u2013Positive Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}